Press Releases & News

-Total gross proceeds from the transaction, before payment of transaction expenses, expected to be up to $82 million assuming no redemptions, combining a possible PIPE financing of up to $40 million and up to $42 million held in First Light trust account -Cash resources will…

Calidi was awarded $3.1 million to support the development of Supernova-1 (SNV1) program through IND application City of Hope, a cancer research and treatment organization, was awarded $12 million to support a Phase 1 physician-sponsored clinical trial evaluating Calidi’s licensed oncolytic virotherapy NeuroNova-2 (NNV2) platform…

LA JOLLA, Calif. (December 6, 2022) -- Calidi Biotherapeutics, Inc. (Calidi), a clinical-stage biotechnology company that is pioneering allogeneic cell-based platforms to revolutionize oncolytic virus therapies, today announced an upcoming presentation at the 7th Annual Oncolytic Virotherapy Summit, taking place in Boston, Massachusetts and virtually, December 6-8, 2022.…

LA JOLLA, CALIF (November 7, 2022) -- Calidi Biotherapeutics, Inc. (Calidi), a clinical-stage biotechnology company that is pioneering allogeneic cell-based platforms to revolutionize oncolytic virus therapies, today announced the presentation of new pre-clinical data from the company’s SuperNova-1 (SNV1) platform at the upcoming Society for…

LA JOLLA, CALIF (October 12, 2022)-- Calidi Biotherapeutics, Inc. (Calidi), a clinical-stage biotechnology company that is pioneering allogeneic cell-based platforms to revolutionize oncolytic virus therapies, today announced a poster presentation highlighting pre-clinical data from the company’s SuperNova1 (SNV1) program at the upcoming Society for Immunotherapy of…

LA JOLLA, CALIF (September 27, 2022) -- Calidi Biotherapeutics, Inc. (Calidi), a clinical-stage biotechnology company that is pioneering allogeneic cell-based platforms to revolutionize oncolytic virus therapies, today announced the appointment of David Sans, FAARM, Ph.D, MBA, in New York as Head of Corporate Development. In…

LA JOLLA, CALIF (September 8, 2022)-- Calidi Biotherapeutics, Inc. (Calidi), a clinical-stage biotechnology company that is pioneering allogeneic cell-based platforms to revolutionize oncolytic virus therapies, today announced that senior management will present a company overview at two upcoming investor conferences: SALT New York 2022 on Monday,…

LA JOLLA, CALIF--August 2, 2022--(BUSINESS WIRE)--Calidi Biotherapeutics, Inc. (Calidi), a clinical-stage biotechnology company that is pioneering allogeneic cell-based platforms to revolutionize oncolytic virus therapies, is pleased to announce that City of Hope has received U.S. Food and Drug Administration (FDA) authorization to proceed with a…

LA JOLLA, Calif. – June 28, 2022 – Calidi Biotherapeutics, Inc., a clinical-stage biotechnology company that is pioneering the development of stem cell-based delivery of oncolytic viruses, today announced the appointment of W.K. Alfred Yung, M.D., Professor, Neuro-Oncology at the MD Anderson Cancer Center, to…

LA JOLLA, Calif., — Calidi Biotherapeutics, Inc., a clinical-stage biotechnology company pioneering the development of stem cell-based delivery of oncolytic viruses, today announced that Stephen Thesing, Chief Business Officer, will present a company overview at the Jefferies Healthcare Conference on Wednesday, June 8, 2022 at…